MétaCan
Menu
Back to cohort

New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma

2025· article· en· W4413139122 on OpenAlexaff
Uri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, Soyoung Kim, Amy Moskop, Temitope Oloyede, Farrukh T. Awan, Veronika Bachanová, Talha Badar, Merav Bar, Pere Barba, Amer Beitinjaneh, Amanda F. Cashen, Bhagirathbhai Dholaria, Umar Farooq, Jessica Foglesong, Siddhartha Ganguly, Peiman Hematti, LaQuisa C. Hill, Michael D. Jain, Tania Jain, Partow Kebriaei, Adam S. Kittai, Frederick L. Locke, Premal Lulla, Joseph P. McGuirk, Elena Mead, Alberto Mussetti, Taiga Nishihori, Amanda Olson, Martina Pennisi, Miguel‐Angel Perales, Praveen Ramakrishnan Geethakumari, Peter A. Riedell, Wael Saber, Roni Shouval, Elizabeth J. Shpall, Margarida Magalhaes‐Silverman, Christopher Strouse, Cameron J. Turtle, Anusha Valluripalli, Kitsada Wudhikarn, Marcelo C. Pasquini, Sairah Ahmed, Mohamed L. Sorror

Bibliographic record

VenueBlood Advances · 2025
Typearticle
Languageen
FieldMedicine
TopicCAR-T cell therapy research
Canadian institutionsDalhousie University
FundersLegend BiotechPharmacyclicsEurostarsGenentechNational Institutes of HealthJuno TherapeuticsAstellas PharmaSwedish Orphan BiovitrumOmeros CorporationBeiGenePfizerIncytebluebird bioJazz PharmaceuticalsNational Cancer InstituteServierGilead SciencesMoffitt Cancer CenterSociety for Immunotherapy of CancerCidara TherapeuticsCelgeneFred Hutchinson Cancer Research CenterKaryopharm TherapeuticsMemorial Sloan-Kettering Cancer CenterMassachusetts General HospitalAmgenBristol-Myers Squibb
KeywordsMedicineComorbidityInternal medicineHazard ratioLymphomaDiabetes mellitusGastroenterologyConfidence interval

Abstract

fetched live from OpenAlex

ABSTRACT: The cumulative impact of baseline comorbidities on outcomes of chimeric antigen receptor T-cell (CAR-T) therapy is not well established. Therefore, we developed and validated a Cellular Therapy Comorbidity Index (CT-CI) to predict outcomes following CD19-directed CAR-T therapy for large B-cell lymphoma (LBCL). Patients aged 18 or older receiving commercial CAR-T therapy for LBCL during 2017 to 2020 were selected from the Center for International Blood and Marrow Transplant Research registry. Patients were randomly assigned to training or validation cohorts. Comorbidities given weighted scores comprised the CT-CI, which was then validated for overall survival (OS) prognostication. A total of 1916 patients from 97 medical centers were included, with a median age of 64 years (19-91 years). About 70% of patients had comorbidities, such as cardiac disease (12%); diabetes (14%); hepatic dysfunction (mild, 8%; moderate to severe, 2%); psychiatric disturbance (18%); and pulmonary dysfunction (moderate, 15%; severe, 12%). The CT-CI was calculated, stratified patients in 3 categories, and was associated with increased mortality. Patients with higher CT-CI scores had worse OS (CT-CI 1: hazard ratio [HR], 1.37 [95% confidence interval [CI], 1.16-1.62; P < .001]; CT-CI 2: HR, 1.49 [95% CI, 1.17-1.89; P = .001]; CT-CI ≥ 3: HR, 2.55 [95% CI, 1.90-3.42; P< .001]). Higher CT-CI scores predicted treatment-related mortality and relapse. There was no correlation between the CT-CI score and CAR-T-related toxicities. The novel CT-CI score stratifies the effect of patient comorbidities on survival after CAR-T therapy and can be used for clinical decision-making and treatment selection in high-risk populations. However, comorbidities and fear of increased toxicity should not preclude patients from this effective therapy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.606
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.295
Teacher spread0.281 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueBlood AdvancesSame topicCAR-T cell therapy researchFrench-language works237,207